Edwards Lifesciences (EW) Tops Q3 EPS by 9c, Q4 & FY Guidance Tops Views

Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $1.07, $0.09 better than the analyst estimate of $0.98. Revenue for the quarter came in at $615 million versus the consensus estimate of $598.29 million.

Edwards Lifesciences sees FY2015 EPS of $4.43-$4.53, versus the consensus of $4.37. Edwards Lifesciences sees FY2015 revenue of $2.3-2.5 million, versus the consensus of $2.44 million.

Edwards Lifesciences sees Q4 2015 EPS of $1.11-$1.21, versus the consensus of $1.14. Edwards Lifesciences sees Q4 2015 revenue of $620-660 million, versus the consensus of $630.20 million.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
• BofA starts bullish Alvotech coverage on biosimilar launch cycle
• Morgan Stanley starts Rio Tinto ADR coverage at underweight, sees 14% downside